Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1992 Mar;51(3):353–357. doi: 10.1136/ard.51.3.353

Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus.

H J Out 1, M van Vliet 1, P G de Groot 1, R H Derksen 1
PMCID: PMC1004660  PMID: 1575581

Abstract

Fluctuations of lupus anticoagulant activity and anticardiolipin antibody titres were studied in 53 patients with systemic lupus erythematosus (SLE). The median study time was 26 months with a median number of 12 samples. Lupus anticoagulant was measured by the kaolin clotting time (KCT) and dilute Russell viper venom time (dRVVT) assays; anticardiolipin antibodies were assayed by an enzyme linked immunosorbent assay (ELISA). Normal and increased KCTs or dRVVTs were seen during follow up in 13 and 12 patients, respectively. IgG anticardiolipin antibodies changed from negative to positive or positive to negative in 26 patients and IgM anticardiolipin antibodies in 16 patients. Disease activity and treatment with prednisone could account for these fluctuations in the kaolin clotting time (KCT) in 7 of 13 patients and in the dRVVT in 2 of 12 patients. Whole group analysis showed that the KCT, dRVVT, and IgM anticardiolipin antibodies were not associated with disease activity, in contrast with IgG anticardiolipin antibodies. During treatment with prednisone normal KCT and dRVVT results were obtained more easily than normal anticardiolipin antibody levels. It is recommended that lupus patients should not be classified as antiphospholipid antibody positive or negative on the basis of only one sample.

Full text

PDF
353

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D. Pathogenetic potential of antiphospholipid antibodies. J Rheumatol. 1988 Jun;15(6):890–893. [PubMed] [Google Scholar]
  2. Asherson R. A., Khamashta M. A., Ordi-Ros J., Derksen R. H., Machin S. J., Barquinero J., Outt H. H., Harris E. N., Vilardell-Torres M., Hughes G. R. The "primary" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989 Nov;68(6):366–374. [PubMed] [Google Scholar]
  3. Branch D. W., Scott J. R., Kochenour N. K., Hershgold E. Obstetric complications associated with the lupus anticoagulant. N Engl J Med. 1985 Nov 21;313(21):1322–1326. doi: 10.1056/NEJM198511213132104. [DOI] [PubMed] [Google Scholar]
  4. Derksen R. H., Biesma D., Bouma B. N., Gmelig Meyling F. H., Kater L. Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum. 1986 Oct;29(10):1295–1296. doi: 10.1002/art.1780291021. [DOI] [PubMed] [Google Scholar]
  5. Derksen R. H., Hasselaar P., Blokzijl L., Gmelig Meyling F. H., De Groot P. G. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis. 1988 May;47(5):364–371. doi: 10.1136/ard.47.5.364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Derksen R. H., Kater L. Lupus anticoagulant: revival of an old phenomenon. Clin Exp Rheumatol. 1985 Oct-Dec;3(4):349–357. [PubMed] [Google Scholar]
  7. Harris E. N., Asherson R. A., Hughes G. R. Antiphospholipid antibodies--autoantibodies with a difference. Annu Rev Med. 1988;39:261–271. doi: 10.1146/annurev.me.39.020188.001401. [DOI] [PubMed] [Google Scholar]
  8. Hughes G. R., Asherson R. A., Khamashta M. A. Antiphospholipid syndrome: linking many specialties. Ann Rheum Dis. 1989 May;48(5):355–356. doi: 10.1136/ard.48.5.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kalunian K. C., Peter J. B., Middlekauff H. R., Sayre J., Ando D. G., Mangotich M., Hahn B. H. Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. Am J Med. 1988 Nov;85(5):602–608. doi: 10.1016/s0002-9343(88)80229-8. [DOI] [PubMed] [Google Scholar]
  10. Loizou S., McCrea J. D., Rudge A. C., Reynolds R., Boyle C. C., Harris E. N. Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): standardization and quantitation of results. Clin Exp Immunol. 1985 Dec;62(3):738–745. [PMC free article] [PubMed] [Google Scholar]
  11. Lubbe W. F., Butler W. S., Palmer S. J., Liggins G. C. Fetal survival after prednisone suppression of maternal lupus-anticoagulant. Lancet. 1983 Jun 18;1(8338):1361–1363. doi: 10.1016/s0140-6736(83)92141-4. [DOI] [PubMed] [Google Scholar]
  12. Out H. J., de Groot P. G., Hasselaar P., dan Vliet M., Derksen R. H. Fluctuations of anticardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis. 1989 Dec;48(12):1023–1028. doi: 10.1136/ard.48.12.1023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rosner E., Pauzner R., Lusky A., Modan M., Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost. 1987 Apr 7;57(2):144–147. [PubMed] [Google Scholar]
  14. Shergy W. J., Kredich D. W., Pisetsky D. S. The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus. J Rheumatol. 1988 Sep;15(9):1389–1394. [PubMed] [Google Scholar]
  15. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  16. Thiagarajan P., Pengo V., Shapiro S. S. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood. 1986 Oct;68(4):869–874. [PubMed] [Google Scholar]
  17. Vaarala O., Palosuo T., Kleemola M., Aho K. Anticardiolipin response in acute infections. Clin Immunol Immunopathol. 1986 Oct;41(1):8–15. doi: 10.1016/0090-1229(86)90046-2. [DOI] [PubMed] [Google Scholar]
  18. ter Borg E. J., Horst G., Hummel E. J., Limburg P. C., Kallenberg C. G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990 May;33(5):634–643. doi: 10.1002/art.1780330505. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES